Want to see AVTX full AI Analyst Report?
Top Page
Avalo Therapeutics
(NASDAQ:AVTX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$14.00
▼(-29.08% Downside)
Action:Reiterated
Date:08/06/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, and ongoing cash burn). Technical indicators are moderately supportive (price above key moving averages with neutral momentum), and corporate events are a mild positive due to pipeline updates and strengthened funding—though dilution risk remains. Valuation is also constrained by loss-making status (negative P/E) and no dividend support.
Positive Factors
Low Leverage
Currently low leverage reduces near-term solvency pressure and gives the company more financial flexibility than a heavily indebted development-stage biotech. This supports continued investment in clinical programs while limiting the immediate burden of debt service and refinancing obligations.
Negative Factors
Minimal and Declining Revenue
Minimal and declining revenue indicates that AVTX has not yet established a meaningful commercial revenue base. This leaves the company dependent on clinical progress and future product or partnership success, making near-term operating performance highly vulnerable to development outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Currently low leverage reduces near-term solvency pressure and gives the company more financial flexibility than a heavily indebted development-stage biotech. This supports continued investment in clinical programs while limiting the immediate burden of debt service and refinancing obligations.
Read all positive factors
Avalo Therapeutics (AVTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$710.06M
Dividend YieldN/A
Average Volume (3M)1.05M
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth-86.62%
EPS Growth14.74%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.74
Shares Outstanding53,629,990
10 Day Avg. Volume944,499
30 Day Avg. Volume1,053,993
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.93
Price to Sales (P/S)4125.96
P/FCF Ratio-4.73
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue6.91K
Enterprise Value/Gross Profit-40.98
Enterprise Value/Ebitda-4.07
Forecast
1Y Price Target
$46.20Price Target Upside134.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.92
Revenue Forecast (FY)N/A
Avalo Therapeutics Business Overview & Revenue Model
Company Description
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immun...
Avalo Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
55
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 59.00K | 59.00K | 441.00K | 1.92M | 18.05M | 5.40M |
| Gross Profit | -9.95M | 59.00K | 807.00K | 640.00K | 14.62M | 3.91M |
| EBITDA | -100.05M | -77.75M | -34.85M | -23.29M | -37.29M | -80.50M |
| Net Income | -100.33M | -78.26M | -35.13M | -31.54M | -41.66M | -84.38M |
Balance Sheet | ||||||
| Total Assets | 490.78M | 116.46M | 150.73M | 20.99M | 33.37M | 80.21M |
| Cash, Cash Equivalents and Short-Term Investments | 400.28M | 98.34M | 134.55M | 7.42M | 13.17M | 54.59M |
| Total Debt | 242.00K | 2.43M | 568.00K | 537.00K | 19.95M | 33.32M |
| Total Liabilities | 42.12M | 33.41M | 17.70M | 13.69M | 44.28M | 57.13M |
| Stockholders Equity | 448.66M | 83.05M | 133.03M | 7.30M | -10.91M | 23.08M |
Cash Flow | ||||||
| Free Cash Flow | -66.38M | -51.46M | -49.06M | -30.84M | -26.85M | -71.00M |
| Operating Cash Flow | -66.38M | -51.46M | -49.06M | -30.68M | -26.75M | -70.89M |
| Investing Cash Flow | -315.28M | -81.72M | 356.00K | -133.00K | -95.00K | -113.00K |
| Financing Cash Flow | 855.87M | 14.59M | 175.85M | 25.04M | -14.70M | 106.76M |
Avalo Therapeutics Technical Analysis
Negative
19.74
Price Trends
17.52
Negative
17.26
Negative
16.58
Negative
Market Momentum
-1.17
Positive
27.32
Positive
20.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTX, the sentiment is Negative. The current price of 19.74 is above the 20-day moving average (MA) of 15.15, above the 50-day MA of 17.52, and above the 200-day MA of 16.58, indicating a bearish trend. The MACD of -1.17 indicates Positive momentum. The RSI at 27.32 is Positive, neither overbought nor oversold. The STOCH value of 20.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVTX.
Avalo Therapeutics Risk Analysis
Avalo Therapeutics disclosed 80 risk factors in its most recent earnings report. Avalo Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Avalo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $710.06M | -2.79 | -58.03% | ― | -86.62% | 14.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $100.28M | -1.17 | -288.36% | ― | ― | 21.42% | |
48 Neutral | $58.50M | -0.33 | -1625.88% | ― | -100.00% | 46.66% | |
44 Neutral | $101.93M | -0.81 | -87.05% | ― | ― | -29.66% | |
42 Neutral | $50.93M | -0.88 | -1266.43% | ― | ― | 49.43% |
* Healthcare Sector Average
AVTX
Avalo Therapeutics
13.24
-0.43
-3.15%
CRBP
Corbus Pharmaceuticals
5.27
-11.05
-67.71%
MIST
Milestone Pharmaceuticals
0.81
-1.19
-59.55%
ELTX
Elicio Therapeutics
1.88
-8.77
-82.35%
GUTS
Fractyl Health, Inc.
4.41
-11.67
-72.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.